Barbara Bush Foundation Partners with Barbershop Books and Penguin Young Readers to Provide Child-Friendly Reading Spaces in Baltimore and Detroit Barbershops

WASHINGTON, Aug. 3, 2020 /PRNewswire/ — The Barbara Bush Foundation for Family Literacy has partnered with Barbershop Books and Penguin Young Readers to provide child-friendly reading spaces and early literacy training to help expand reading opportunities for Black boys in Baltimore and Detroit.

WASHINGTON, Aug. 3, 2020 /PRNewswire/ — The Barbara Bush Foundation for Family Literacy has partnered with Barbershop Books and Penguin Young Readers to provide child-friendly reading spaces and early literacy training to help expand reading opportunities for Black boys in Baltimore and Detroit.

Developed in Harlem, Barbershop Books is a community-based program that leverages the cultural significance of barbershops in Black communities. The initiative, which targets Black boys who are four to eight years old, increases boys’ access to high quality children’s books, and works to increase out-of-school time reading among young Black boys. The program also provides literacy training to participating barbers. Barbershop Books is currently active in 21 states including California, Florida, Illinois, Maryland, Michigan, New York, Texas and Virginia.

«The news-making events of 2020 have highlighted the systemic injustices and disadvantages faced by Black Americans. We believe that literacy is the great equalizer and it is imperative that we give every family the knowledge and resources they need to live with opportunity and dignity,» said British A. Robinson, Barbara Bush Foundation President and CEO. «We are thrilled to partner with Barbershop Books to support its vital work to empower Black families and communities through literacy.»

Through this partnership, the Barbara Bush Foundation will help Barbershop Books launch new reading spaces and provide early literacy training to barbers in 10 barbershops in Baltimore, and will support 20 existing reading spaces in Detroit. The Foundation will also provide family literacy resources, including access to a free adult literacy app for parents and caregivers who wish to improve their own literacy skills without attending classes.

According to the United States Department of Education, more than 85% of America’s Black male fourth grade students are not proficient in reading. In an increasingly global and knowledge-based economy, poor reading skills among young Black boys today will produce Black men who are unprepared to compete in the workforce of tomorrow. Four key factors contribute to low reading proficiency among Black boys: 1) limited access to engaging reading material, 2) lack of Black men in Black boys’ early reading experiences, 3) few culturally competent educators, and 4) educational systems that are unresponsive to Black boys’ individual learning needs.

Barbershop Books was founded in 2013 by Alvin Irby to increase out of school reading time among young Black boys. Irby is a nationally recognized speaker and award-winning social entrepreneur, as well as a cultural competency specialist and a thought leader in the field of early childhood education.

«With libraries limited in the services they can provide and some form of distance learning becoming the new norm for young learners, we must think creatively and act courageously to ensure vulnerable children have the reading support they need outside of school,» said Irby. «By increasing access to fun books and Black male reading role models, Barbershop Books endeavors to help create the type of early positive reading experiences that help Black boys to identify as readers – and thus inspire them to read for fun.»

In support of this initiative, Penguin Young Readers has donated culturally relevant, age appropriate books to help participating children – who have reduced access to community and school libraries during the COVID-19 crisis – build their own home libraries. Among the titles provided by Penguin are selections from #1 New York Times bestselling author Brad Meltzer’s Ordinary People Change the World series and other kid-friendly titles.

«We admire the important work Barbershop Books is doing to support childhood literacy within Black communities and we are honored to partner with them and the Barbara Bush Foundation for Family Literacy on this important initiative,» said Jen Loja, President, Penguin Young Readers.

«We’re so grateful to Penguin for their generous support of our commitment to Black communities,» said Robinson. «Together, we are making an impact on the lives of Black children and their families – one that is needed now more than ever – that will last for years to come.»

About the Barbara Bush Foundation for Family Literacy: The Barbara Bush Foundation for Family Literacy has been the nation’s leading advocate for family literacy for more than three decades. Established by former First Lady Barbara Bush in 1989, the Foundation is a public charity that envisions an America in which everyone can read, write, and comprehend in order to navigate the world with dignity. To learn more, visit www.BarbaraBush.org.

About Penguin Young Readers: Penguin Young Readers is one of the leading children’s book publishers in the United States. The company owns a wide range of imprints and trademarks, including Dial Books, Dutton, Kokila, Nancy Paulsen Books, Penguin Workshop, Philomel, Puffin, G. P. Putnam’s Sons, Razorbill, Viking, and Frederick Warne. These imprints are home to such award-winning, New York Times bestselling authors as, Laurie Halse Anderson, Max Brallier, Jan Brett, Eric Carle, Roald Dahl, Anna Dewdney, John Flanagan, John Green, Oliver Jeffers, Brad Meltzer, Ransom Riggs, Ruta Sepetys, Sabaa Tahir, Jacqueline Woodson, and dozens of other popular authors. Penguin Young Readers Group is also the proud publisher of perennial brand franchises such as The Little Engine That Could, the Nancy Drew and Hardy Boys series, Peter Rabbit, Spot, the Classic Winnie the Pooh, the Very Hungry Caterpillar, Madeline, Mad Libs, the Last Kids on Earth, the Rangers Apprentice, and Who HQ among many others. Penguin Young Readers Group is a division of Penguin Random House LLC.

About Barbershop Books: Barbershop Books is the debut program of Reading Holiday Project, Inc., a 501(c)(3) nonprofit literacy organization in New York City. Developed in Harlem, Barbershop Books is a community-based program that creates child-friendly reading spaces in barbershops and provides early literacy training to barbers across America. It leverages the cultural significance of barbershops in Black communities to increase boys’ access to culturally relevant, age appropriate, and gender responsive children’s books and to increase out-of-school time reading among young black boys. www.barbershopbooks.org

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/barbara-bush-foundation-partners-with-barbershop-books-and-penguin-young-readers-to-provide-child-friendly-reading-spaces-in-baltimore-and-detroit-barbershops-301104436.html

SOURCE Barbara Bush Foundation for Family Literacy

Bio-Techne And Kantaro Biosciences To Launch A Quantitative Research Use Only COVID-19 Serology Test

MINNEAPOLIS and NEW YORK, Aug. 3, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid…

MINNEAPOLIS and NEW YORK, Aug. 3, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid distribution of the assay to the vaccine development community.  The COVID-SeroIndex test kit is expected to be available for research use in early August.  

The COVID-SeroIndex test kit is an enzyme-linked immunosorbent assay, or ELISA, designed to measure the presence or absence of anti-COVID-19 antibodies in addition to measuring the titer (level) of antibodies a person has produced.  It utilizes not one, but two virus antigens: the full-length spike protein, and its receptor binding domain. The underlying technology was created by Mount Sinai’s internationally recognized team of virologists and pathologists and has been tested on over 50,000 patient samples.

«The launch of a RUO version of the COVID-19 serology test brings to the research community what we believe is the highest quality SARS-CoV-2 antibody assay available,» commented Dave Eansor, Bio-Techne’s Protein Sciences Segment President.  «The assay supports the life cycle of COVID-19 vaccine development, providing researchers with an objective way of measuring antibody titer.»

«The COVID-SeroIndex test kit is a natural extension of the previously announced Bio-Techne and Kantaro partnership,» said Chuck Kummeth, President and Chief Executive Officer of Bio-Techne.  «We are hopeful that this assay can accelerate the near-term launch of a successful COVID-19 vaccine due to its high level of accuracy and robustness.»

«Mount Sinai has invested heavily in this technology and in leading research and clinical care for COVID-19. We recognized the need to deliver a high-quality, accurate assay and there has been immense development and application of the underlying technology for this test at Mount Sinai,» said Erik Lium, PhD, Executive Vice President and Chief Commercial Innovation Officer at Mount Sinai. «We’re thrilled to launch this additional research assay with Bio-Techne, continue building our understanding of COVID-19, and make this tool available globally to researchers.»

Forward Looking Statements:

Bio-Technes press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect Bio-Technes actual results: the market for and introduction, acceptance and performance of new products, obtaining the appropriate regulatory approvals, the impact of the growing number of producers of biotechnology products, including COVID-19 testing products, and related price competition, general economic conditions, manufacturing and supply chain disruptions, and the potential impact of COVID-19 on our operations or financial results.

For additional information concerning these and other such factors, see the section titled «Risk Factors» in Bio-Technes annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. Bio-Techne undertakes no obligation to update or revise any forward-looking statements made in its press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

About Bio-Techne

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $714 million in net sales in fiscal 2019 and has over 2,300 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com.

Contact: 
David Clair, Senior Director, Investor Relations & Corporate Development
david.clair@bio-techne.com

About Kantaro Biosciences

Kantaro Biosciences («Kantaro»), a Mount Sinai Health System venture in partnership with RenalytixAI, is dedicated to ensuring that high-quality diagnostic tests for critical health challenges are accessible. The company provides rigorous, results-driven and reproducible diagnostics to advance the care and well-being of people, communities and society. Kantaro specializes in the rapid scale-up of groundbreaking diagnostic innovations and the creation of partnerships to bring these crucial technologies to market. For more information, visit www.kantarobio.com.

About the Mount Sinai Health System

The Mount Sinai Health System is New York Citys largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Reports «Honor Roll» of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians are in the top 1% of all physicians nationally by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

About Renalytix AI

Renalytix AI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Companys products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com

Bio-Techne

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bio-techne-and-kantaro-biosciences-to-launch-a-quantitative-research-use-only-covid-19-serology-test-301104261.html

SOURCE Bio-Techne Corporation

Bio-Techne And Kantaro Biosciences To Launch A Quantitative Research Use Only COVID-19 Serology Test

MINNEAPOLIS and NEW YORK, Aug. 3, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid…

MINNEAPOLIS and NEW YORK, Aug. 3, 2020 /PRNewswire/ — Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid distribution of the assay to the vaccine development community.  The COVID-SeroIndex test kit is expected to be available for research use in early August.  

The COVID-SeroIndex test kit is an enzyme-linked immunosorbent assay, or ELISA, designed to measure the presence or absence of anti-COVID-19 antibodies in addition to measuring the titer (level) of antibodies a person has produced.  It utilizes not one, but two virus antigens: the full-length spike protein, and its receptor binding domain. The underlying technology was created by Mount Sinai’s internationally recognized team of virologists and pathologists and has been tested on over 50,000 patient samples.

«The launch of a RUO version of the COVID-19 serology test brings to the research community what we believe is the highest quality SARS-CoV-2 antibody assay available,» commented Dave Eansor, Bio-Techne’s Protein Sciences Segment President.  «The assay supports the life cycle of COVID-19 vaccine development, providing researchers with an objective way of measuring antibody titer.»

«The COVID-SeroIndex test kit is a natural extension of the previously announced Bio-Techne and Kantaro partnership,» said Chuck Kummeth, President and Chief Executive Officer of Bio-Techne.  «We are hopeful that this assay can accelerate the near-term launch of a successful COVID-19 vaccine due to its high level of accuracy and robustness.»

«Mount Sinai has invested heavily in this technology and in leading research and clinical care for COVID-19. We recognized the need to deliver a high-quality, accurate assay and there has been immense development and application of the underlying technology for this test at Mount Sinai,» said Erik Lium, PhD, Executive Vice President and Chief Commercial Innovation Officer at Mount Sinai. «We’re thrilled to launch this additional research assay with Bio-Techne, continue building our understanding of COVID-19, and make this tool available globally to researchers.»

Forward Looking Statements:

Bio-Technes press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect Bio-Technes actual results: the market for and introduction, acceptance and performance of new products, obtaining the appropriate regulatory approvals, the impact of the growing number of producers of biotechnology products, including COVID-19 testing products, and related price competition, general economic conditions, manufacturing and supply chain disruptions, and the potential impact of COVID-19 on our operations or financial results.

For additional information concerning these and other such factors, see the section titled «Risk Factors» in Bio-Technes annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. Bio-Techne undertakes no obligation to update or revise any forward-looking statements made in its press releases due to new information or future events. Investors are cautioned not to place undue emphasis on these statements.

About Bio-Techne

Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $714 million in net sales in fiscal 2019 and has over 2,300 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com.

Contact: 
David Clair, Senior Director, Investor Relations & Corporate Development
david.clair@bio-techne.com

About Kantaro Biosciences

Kantaro Biosciences («Kantaro»), a Mount Sinai Health System venture in partnership with RenalytixAI, is dedicated to ensuring that high-quality diagnostic tests for critical health challenges are accessible. The company provides rigorous, results-driven and reproducible diagnostics to advance the care and well-being of people, communities and society. Kantaro specializes in the rapid scale-up of groundbreaking diagnostic innovations and the creation of partnerships to bring these crucial technologies to market. For more information, visit www.kantarobio.com.

About the Mount Sinai Health System

The Mount Sinai Health System is New York Citys largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Reports «Honor Roll» of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians are in the top 1% of all physicians nationally by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

About Renalytix AI

Renalytix AI is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Companys products are being designed to make significant improvements in kidney disease diagnosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com

Bio-Techne

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bio-techne-and-kantaro-biosciences-to-launch-a-quantitative-research-use-only-covid-19-serology-test-301104261.html

SOURCE Bio-Techne Corporation

Joint Helmet Mounted Cueing System (JHMCS) II Undergoes Flight Testing Aboard F-16V

FORT WORTH, Texas, Aug. 3, 2020 /PRNewswire/ — JHMCS II, the newest member of the Joint Helmet Mounted Cueing System family of products, is being flight tested aboard the Lockheed Martin F-16V aircraft in the United States. This follows the completion of JHMCS II safety qualification testing, including windblast, tower and sled tests.

FORT WORTH, Texas, Aug. 3, 2020 /PRNewswire/ — JHMCS II, the newest member of the Joint Helmet Mounted Cueing System family of products, is being flight tested aboard the Lockheed Martin F-16V aircraft in the United States. This follows the completion of JHMCS II safety qualification testing, including windblast, tower and sled tests.

These flight tests are part of the U.S. Air Force’s Military Flight Release (MFR) for the F-16V launch customer, a critical milestone that signifies the aircraft and its subsystems have met specification performance, safety, reliability, and maintainability criteria.  The JHMCS II is the only Helmet Mounted Display (HMD) integrated and tested on the F-16V. 

JHMCS II incorporates key new technological advancements while drawing on the strong legacy of the JHMCS family of HMDs. It features visor-projected symbology, an optical/inertial tracker and up-look reticles that fully exploit high off-boresight visual cueing and targeting for advanced weaponry, avionics and sensors. A day display module and a night module enabling modified -4949 Aviator Night Vision Goggles provide symbology in all flight conditions with one-handed in-flight switching capability.

«JHMCS II is designed to increase lethality, mission effectiveness and pilot safety,» said Raanan Horowitz, President and CEO of Elbit Systems of America. «The helmet mounted display’s improved center of gravity reduces neck strain which increases pilot safety and comfort.»

As the formal baseline Helmet Mounted Display (HMD) of F-16V and F-16 block 70/72 aircraft, the JHMCS II already has been selected by several international customers. In addition, variants of JHMCS II were selected by other air forces worldwide to equip a wide range of fighter aircraft. More than 6,000 JHMCS HMDs have been supplied to military pilots in dozens of countries. 

«Flight testing is the next milestone as we partner with Collins Elbit Vision Systems on the JHMCS II, and we look forward to continued collaboration,» says Danya Trent, Vice President, F-16 for Lockheed Martin. «We are incredibly proud to support F-16 pilots with this cutting-edge technology, enabling their critical missions around the world.»

The JHMCS II is manufactured and delivered through Collins Elbit Vision Systems (CEVS), a joint venture between Collins Aerospace and Elbit Systems of America.

About Elbit Systems of America, LLC

Elbit Systems of America, headquartered in Fort Worth, Texas, is a leading provider of high-performance products, system solutions, and support services focusing on the defense, homeland security, law enforcement, commercial aviation, and medical instrumentation markets. With facilities throughout the U.S., Elbit America is dedicated to supporting those who contribute daily to the safety and security of the United States. Elbit Systems of America, LLC is wholly owned by Elbit Systems Ltd. (NASDAQ: ESLT and TASE: ESLT), a global high technology company engaged in a wide range of programs for innovative defense and commercial applications. For additional information, visit: www.elbitsystems-us.com or follow us on Twitter, LinkedIn and Instagram.

About Elbit Systems

Elbit Systems Ltd. is an international high technology company engaged in a wide range of defense, homeland security and commercial programs throughout the world. The Company, which includes Elbit Systems and its subsidiaries, operates in the areas of aerospace, land, and naval systems, command, control, communications, computers, intelligence surveillance and reconnaissance («C4ISR»), unmanned aircraft systems, advanced electro-optics, electro-optic space systems, EW suites, signal intelligence systems, data links and communications systems, radios and cyber-based systems and munitions. The Company also focuses on the upgrading of existing platforms, developing new technologies for defense, homeland security and commercial applications and providing a range of support services, including training and simulation systems. For additional information, visit: https://elbitsystems.com/, follow us on Twitter or visit our official Facebook, YouTube and LinkedIn Channels.

Trademarks

Elbit Systems of America and other trademarks, service marks and logos are registered or unregistered marks of Elbit Systems of America companies in the United States and in foreign countries. Copyright ©2020 Elbit Systems of America. All rights reserved.

Forward Looking Statement

This press release may contain forward–looking statements (within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended and the Israeli Securities Law, 1968) regarding Elbit Systems Ltd. and/or its subsidiaries (collectively the Company), to the extent such statements do not relate to historical or current facts. Forward-looking statements are based on management’s current expectations, estimates, projections and assumptions about future events. Forward–looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guaranteeing of future performance and involve certain risks, uncertainties and assumptions about the Company, which are difficult to predict, including projections of the Company’s future financial results, its anticipated growth strategies and anticipated trends in its business.  Therefore, actual future results, performance and trends may differ materially from these forward–looking statements due to a variety of factors, including, without limitation: scope and length of customer contracts; governmental regulations and approvals; changes in governmental budgeting priorities; general market, political and economic conditions in the countries in which the Company operates or sells, including Israel and the United States among others; changes in global health and macro-economic conditions; differences in anticipated and actual program performance, including the ability to perform under long-term fixed-price contracts; changes in the competitive environment; and the outcome of legal and/or regulatory proceedings.  The factors listed above are not all-inclusive, and further information is contained in Elbit Systems Ltd.’s latest annual report on Form 20-F, which is on file with the U.S. Securities and Exchange Commission. All forward–looking statements speak only as of the date of this release. Although the Company believes the expectations reflected in the forward-looking statements contained herein are reasonable, it cannot guarantee future results, level of activity, performance or achievements. Moreover, neither the Company nor any other person assumes responsibility for the accuracy and completeness of any of these forward-looking statements. The Company does not undertake to update its forward-looking statements.

Elbit Systems Ltd., its logo, brand, product, service and process names appearing in this Press Release are the trademarks or service marks of Elbit Systems Ltd. or its affiliated companies.  All other brand, product, service and process names appearing are the trademarks of their respective holders.  Reference to or use of a product, service or process other than those of Elbit Systems Ltd. does not imply recommendation, approval, affiliation or sponsorship of that product, service or process by Elbit Systems Ltd. Nothing contained herein shall be construed as conferring by implication, estoppel or otherwise any license or right under any patent, copyright, trademark or other intellectual property right of Elbit Systems Ltd. or any third party, except as expressly granted herein.

Media Contacts:

Greg Caires | +1-682-286-2299 | greg.caires@elbitsystems-us.com

Amy Hartley I +1-682-286-2411 I amy.hartley@elbitsystems-us.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/joint-helmet-mounted-cueing-system-jhmcs-ii-undergoes-flight-testing-aboard-f-16v-301104554.html

SOURCE Elbit Systems of America, LLC

Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in ALS

NESS ZIONA, Israel, Aug. 3, 2020 /PRNewswire/ — Kadimastem Ltd. (TASE: KDST), a clinical-stage biotechnology company developing cell therapies for the treatment of severe debilitating diseases, announced today that its lead product, AstroRx®, showed a positive efficacy signal and a good safety profile in Cohort B of the Company’s Phase 1/2a clinical trial in ALS.

NESS ZIONA, Israel, Aug. 3, 2020 /PRNewswire/ — Kadimastem Ltd. (TASE: KDST), a clinical-stage biotechnology company developing cell therapies for the treatment of severe debilitating diseases, announced today that its lead product, AstroRx®, showed a positive efficacy signal and a good safety profile in Cohort B of the Company’s Phase 1/2a clinical trial in ALS.

«The current study results are encouraging, as they suggest a clinically meaningful signal of effect. A further randomized, parallel-controlled, clinical trial is needed to confirm these positive effects of AstroRx® in the treatment of ALS,» said Dr. Marc Gotkine, Department of Neurology at Hadassah Medical Center, Jerusalem and the Principal Investigator of the Phase 1/2a clinical trial of AstroRx®. 

Kadimastem CEO Rami Epstein said, «We are excited by the positive and consistent clinical results, demonstrating both the good safety profile and therapeutic effect of AstroRx®. The comparison between the ALSFRS-R change before and after treatment convey a clinically meaningful decline of more than 50% in disease progression rate for a period of 3 months for both cohorts. The effect was even more profound in patients who deteriorate rapidly. Repeated administrations of the treatment, planned to be assessed in future clinical trials, will hopefully extend the duration of the beneficial effect. These results strengthen our commitment to bringing an innovative therapeutic treatment to ALS, a devastating disease currently having no effective treatment.»

Earlier this year, due to COVID-19, the Data Safety Monitoring Board (DSMB) of the Phase 1/2a clinical trial recommended to put additional cohorts on hold to ensure the safety and well-being of the patients. Considering the ongoing situation presented by COVID-19 in Israel, the uncertainty and setbacks imposed, the Company decided to not pursue the additional cohorts of the current Phase 1/2a clinical trial.

«The positive interim results of Cohort A and B strongly support our next global clinical development stages. We are now focused on advancing strategic FDA regulatory processes that will necessitate the conduct of global multi-center clinical trials. In support, the Company is also dedicating resources to production process scale-up as well as to the development of a 2nd generation of AstroRx® as a frozen product that will accelerate our clinical development plan to support market authorization,» added Epstein.

To support these strategic processes, several senior managers with proven experience in leading such global processes have been appointed, including Dasy Mandel as Director of Business Development, Veronique Bellaiche as Director of Regulatory, and most recently Dr. Ruti Alon as the new Chairperson.

Professor Michel Revel, Kadimastem Founder and CSO added, «The strategic plan will benefit the patients and support the efforts of the medical community striving to bring a solution to this devastating disease. We value the contribution of the patients who volunteered to participate in our trial, as well as the physicians and clinical team at Hadassah Medical Center and look forward to continuing our collaboration during the next stages of global clinical trials.»

Study Design

The Phase 1/2a trial is an open label, dose-escalating, clinical study to evaluate the safety, tolerability and preliminary efficacy of AstroRx® cells in patients with ALS. The primary objectives of the trial were safety evaluation and tolerability of a single administration of allogeneic astrocytes derived from human Embryonic Stem Cells (hESC), administered in escalating doses. The secondary objective was to evaluate the efficacy, including ALS Functional Rating Scale-Revised (ALSFRS-R), the gold standard scale to assess ALS progression by monitoring patient muscle functions over time.

In the previously reported Cohort A, 5 patients were administered with a dose of 100X106 AstroRx® cells. In Cohort B, 5 additional patients were treated with a single, higher dose of 250×106 AstroRx® cells. Treatment was provided concomitantly with standard-of-care.

Primary Objective: Safety

Similarly to Cohort A, no treatment-related serious adverse events nor dose-limiting toxicities were reported and the treatment was well tolerated in the higher cell dose.

Secondary Objective: Efficacy

To identify decline in disease progression following treatment, ALSFRS-R slope analysis was performed and compared between the pre- and post-treatment periods. The starting point for the slope of the post-treatment period was referred to in the slope analysis in two ways: at first visit after treatment (Day 30, as previously published for Cohort A) and before treatment administration (Day -1). Both analyses were conducted.

  • The rate of ALS disease progression in Cohort B patients, as assessed by the ALSFRS-R slope difference between pre-treatment and post-treatment (from Day -1) periods, was significantly reduced from -1.43/month during the 3-4 month run-in period before treatment to -0.78/month during 3-month follow-up after treatment, reflecting a clinically meaningful signal and statistically significant (p=0.0023) decline of 45% in disease progression rate.
  • The rate of ALS disease progression in Cohort B patients, as assessed by the ALSFRS-R slope difference between pre-treatment and post-treatment (from Day 30) periods, was significantly reduced from -1.42/month in the pre-treatment period to -0.41/month in the post-treatment period (p=0.0006), reflecting a decline of 71% in disease progression rate.

 

  • Pooling the data of the two Cohorts treated with AstroRx® (n=10, from Day -1) exhibited an even more robust and clinically meaningful effect: 
    – The ALSFRS-R slope was significantly reduced from -1.15/month in the pre-treatment period to a rate of -0.54/month post-treatment (p=0.0004). These results reflect a decline of 53% in disease progression rate.
    – Responder analysis, as assessed by the improvement of at least 25% in the ALSFRS-R rate of decline between pre-treatment and post-treatment periods, demonstrated that 70% of Cohort A & B patients treated with AstroRx® were identified as responders.

 

  • Post-hoc efficacy (by ALSFRS-R) analysis of rapid progressors:
    Rapid progressors are defined as patients who deteriorate at least 1.1 points of ALSFRS-R per month in the run-in period.
    The treatment effect was even higher when assessing the rapid progressor subpopulation of patients from both cohorts (n=5/10, from Day -1): 
    – Slope analysis of ALSFRS-R demonstrated a reduction from -1.58/month in the run-in to -0.65/month during the post treatment, which reflects a decline of 59% in disease progression (p = 0.0003). 
    – Change from baseline in the mean decline of ALSFRS-R during the pre-treatment period in rapid progressors was -4.74 points over 90 days. In contrast, the mean decline in the post-treatment period was reduced to -2.77 over 90 days, a decline of 1.97 ALSFRS-R points per 3 months.
    – In Responder analysis, 80% of rapid progressor patients treated with AstroRx® were identified as responders.

 

The final results of the 6-month follow-up post-treatment for Cohort B are expected in Q4 2020.

About AstroRx®

AstroRx® is a cell therapy product developed and manufactured by Kadimastem at its GMP-compliant facility. AstroRx® contains functional, healthy astrocytes (nervous system support cells) derived from human Embryonic Stem Cells (hESC) that aim to protect diseased motor neurons through several mechanisms of action.

The Company’s technology enables the injection of AstroRx® cells into the cerebrospinal cord fluid (CSF) of patients using a standard lumbar puncture procedure. The goal is to support the malfunctioning cells in the brain and spinal cord of patients suffering from Amyotrophic Lateral Sclerosis (ALS), in order to slow the progression of the disease, improve quality of life and extend life expectancy for these patients. AstroRx® has been granted orphan drug designation by the FDA for the treatment of ALS.

AstroRx® has shown to be safe and effective in preclinical trials and is now being further assessed in a Phase 1/2a open label clinical trial at Hadassah Medical Center, Ein-Kerem, Israel. The objective of the trial is to evaluate the safety, tolerability, and efficacy of escalating doses of AstroRx® cells in patients with ALS. Treatment is administered in addition to the appropriate standard-of-care.

Scientific literature indicates that astrocyte cells play a substantial role in supporting malfunctioning cells also in other neurodegenerative diseases, in addition to ALS. Accordingly, the Company is also evaluating other potential applications of the AstroRx® cell product.

About ALS 

Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive fatal neurodegenerative disease causing dysfunction in the upper and lower motor nerves that control muscle function. ALS leads to muscle weakness, loss of motor function, paralysis, breathing problems, and eventually death. The average life expectancy of ALS patients is 2-5 years. According to the ALS Therapy Development Institute, it is estimated that there are approximately 450,000 ALS patients worldwide of which 30,000 reside in the US. According to the ALS Foundation for Life, the annual average healthcare costs of an ALS patient in the US are estimated at US$ 200,000. Thus, the annual healthcare costs of ALS patients in the US alone amount to US$ 6 Billion.

About Kadimastem

Kadimastem is a clinical stage cell therapy company, developing and manufacturing «off-the-shelf,» allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the Company’s lead product, is an astrocyte cell therapy for the treatment of ALS, currently undergoing a Phase 1/2a clinical trial. IsletRx is the Company’s second product in development. IsletRx is comprised of functional pancreatic islet cells intended to treat patients with insulin dependent diabetes. IsletRx demonstrated safety and efficacy in a proof of concept preclinical study. Kadimastem was founded by Professor Michel Revel, CSO of the Company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST).

Forward Looking Statement

This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company’s control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company’s activity, as well as developments in the general environment and external factors affecting the Company’s activity. The Company’s results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company’s securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should take into account that past performance does not necessarily indicate performance in the future.

Social Media: LinkedIn, Twitter, Facebook

Photo – https://mma.prnewswire.com/media/1222970/Kadimastem_AstroRx_ALS_Trial.jpg

Company Contacts:

Yossi Nizhar, CFO
y.nizhar@kadimastem.com 
+972-73-797-1604 

Marjie Hadad
General Manager
Must Have Communications
marjie@mhc-pr.com 
+1-917-790-1178 (US Press)
+972-54-536-5220 (International and WhatsApp)

Gil Kraiem
Pitch Media
gil@pitch-media.com 
+972-50-570-3090 (Israeli Press)

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/kadimastem-reports-positive-interim-results-of-cohort-b-of-its-astrorx-phase-12a-clinical-trial-in-als-301104553.html

SOURCE Kadimastem

A Sweat-Free School Year: Dermadry Launches 2020 Scholarship For Students Who Sweat Too Much


MONTREAL , Aug. 3, 2020 /PRNewswire/ — Dermadry is back with the second annual edition of its scholarship. The contest is open to students from around the globe who suffer from


MONTREAL , Aug. 3, 2020 /PRNewswire/ — Dermadry is back with the second annual edition of its scholarship. The contest is open to students from around the globe who suffer from hyperhidrosis, a medical condition characterized by excessive sweating that affects approximately 5% of the global population.

Students with hyperhidrosis are faced with a unique set of challenges, which can have a significant impact on quality of life and interfere with their ability to complete daily tasks. Some of these challenges include constantly sweating through school uniforms, shying away from social activities or ruining books, papers, and technology tools due to uncontrollable sweaty hands. It can also lead to an increase in stress and anxiety levels, isolation and bullying.

Submissions

Dermadry is asking students to record themselves discussing their hyperhidrosis story and the impact that excessive sweating has had on their studies and daily life. Submissions are open globally and must be in a video format (minimum 60 seconds).

The prize for the contest is a US$2,000 scholarship and a Dermadry Total device (valued at US$499) to treat the condition. This contest furthers Dermadry’s mission of de-stigmatizing excessive sweating and raising awareness about hyperhidrosis, which is a common but seldom spoken-about condition. The company encourages all applicants over the age of 18 currently enrolled in a post-secondary educational program to come forward and share their stories.

Applicants must upload their completed video to a video-hosting platform (e.g., YouTube) and include a link to their video in their submission that must be completed on Dermadry’s website at this link. Submissions open on Aug. 3, 2020, and close on Aug. 19, 2020, at 11:59 p.m. EDT.

Finalists

Ten finalists will be selected by Dermadry and announced on Aug. 21, 2020. This year, Dermadry is asking participants to use their voice and platform to increase awareness of hyperhidrosis. Four extra finalist spots will be reserved for those with the most engagement on their post about the scholarship on the following platforms: Instagram, TikTok, YouTube, and Twitter. 

The vote will then be open to the public who can cast their votes for the winner on Dermadry’s website. The final vote tally will determine the winner, which will be announced on Aug. 26, 2020.

The contest is open worldwide and entries are welcome in all languages. Dermadry encourages all applicants to be creative. They can share their story, write a song, make an animation or create anything that showcases their creativity and individuality.

For more information and full contest rules, please visit Dermadry’s 2020 scholarship page on its website here. Here’s to a sweat-free school year!

About Dermadry

Dermadry is a Canadian medical device company headquartered in Quebec that manufactures an FDA-cleared iontophoresis device that treats hyperhidrosis. Learn more at dermadry.com and on social media @dermadry. 

Media Contact:

For any media inquiries, please contact media@dermadry.com.

Related Images

dermadry-logo.png
Dermadry Logo

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/a-sweat-free-school-year-dermadry-launches-2020-scholarship-for-students-who-sweat-too-much-301104506.html

SOURCE Dermadry

FDA Accepts and Grants Priority Review of Vanda’s Applications for HETLIOZ® (tasimelteon) in the Treatment of Smith-Magenis Syndrome

WASHINGTON, Aug. 3, 2020 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review Vanda’s applications for Smith-Magenis Syndrome (SMS). The applications include a Supplemental New Drug Application (sNDA) for HETLIOZ® capsules and a New Drug Application (NDA) for the liquid formulation of HETLIOZ® for the treatment of adults and children, respectively, with Smith-Magenis…

WASHINGTON, Aug. 3, 2020 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review Vanda’s applications for Smith-Magenis Syndrome (SMS). The applications include a Supplemental New Drug Application (sNDA) for HETLIOZ® capsules and a New Drug Application (NDA) for the liquid formulation of HETLIOZ® for the treatment of adults and children, respectively, with Smith-Magenis Syndrome (SMS). The FDA has set December 1, 2020 as the target date for its decision under the Prescription Drug User Fee Act (PDUFA-VI).

«The FDA filing of the HETLIOZ® applications for priority review marks a major milestone and brings us closer to providing a critical therapy to patients with SMS,» said Mihael H. Polymeropoulos, M.D., Vanda’s President and CEO. Currently, there are no approved treatments for patients with SMS, a rare orphan disorder affecting approximately 15,000 people in the U.S.

About Smith-Magenis Syndrome

Smith-Magenis Syndrome (SMS) is a developmental disorder that is caused by a small deletion of human chromosome 17p 1,2. In more rare cases SMS is caused by a point mutation in the RAI1 gene which resides in the deleted region. SMS is estimated to affect 1/15,000-25,000 births in the U.S.3  SMS is usually not inherited but rather is due to a de-novo deletion. Patients with SMS present with a number of physical, mental and behavioral problems. The most common symptom of SMS is a severe sleep disorder associated with significant disruption in the lives of patients and their families. 

References:

  1. Williams, S. R., Zies, D., Mullegama, S. V, Grotewiel, M. S., & Elsea, S. H. (2012). Smith-Magenis syndrome results in disruption of CLOCK gene transcription and reveals an integral role for RAI1 in the maintenance of circadian rhythmicity. Am.J Hum.Genet., 90(1537–6605), 941–949.
  2. Gropman, A. L., Duncan, W. C., & Smith, A. C. (2006). Neurologic and developmental features of the Smith-Magenis syndrome (del 17p11.2). Pediatr.Neurol., 34(0887–8994), 337–350. 
  3. Orphanet ORPHA number 819.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on Twitter @vandapharma.

About HETLIOZ®

HETLIOZ® (tasimelteon) is a melatonin receptor agonist. HETLIOZ® has been granted market authorization by the U.S. Food and Drug Administration and the European Medicines Agency. For full U.S. Prescribing Information for HETLIOZ®, including indication and Important Safety Information, visit www.hetlioz.com.

HETLIOZ® IS NOT CURRENTLY APPROVED BY ANY REGULATORY AUTHORITY FOR THE TREATMENT OF SMS.

CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS

Various statements in this release, including, but not limited to statements regarding the target completion date of the FDA’s review of the sNDA and NDA for HETLIOZ® and Vanda’s ability to make HETLIOZ® available to patients with SMS, are «forward-looking statements» under the securities laws. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda’s forward-looking statements include, among others, the ability of the FDA to complete its review of the applications on time and make the determination that HETLIOZ® is safe and effective in the treatment of SMS in adults and children. There can be no assurance that the actual results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements will be achieved. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda’s business and market, particularly those identified in the «Cautionary Note Regarding Forward-Looking Statements», «Risk Factors» and «Management’s Discussion and Analysis of Financial Condition and Results of Operations» sections of Vanda’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as updated by Vanda’s subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Corporate Contact:

AJ Jones II
Chief Corporate Affairs and Communications Officer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

Elizabeth Van Every
Head of Corporate Affairs
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com 

 

Cision View original content:http://www.prnewswire.com/news-releases/fda-accepts-and-grants-priority-review-of-vandas-applications-for-hetlioz-tasimelteon-in-the-treatment-of-smith-magenis-syndrome-301104479.html

SOURCE Vanda Pharmaceuticals Inc.

BD releases FY 2019 Sustainability Report

FRANKLIN LAKES, N.J., Aug. 3, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2019 Sustainability Report, focusing on performance of the environmental, social and governance factors that support the company’s

FRANKLIN LAKES, N.J., Aug. 3, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2019 Sustainability Report, focusing on performance of the environmental, social and governance factors that support the company’s 2020 Sustainability Goals from October 1, 2018 to September 30, 2019 (FY 2019).

BD’s sustainability strategy is driven by its purpose – Advancing the world of health™ – and provides the framework for how it manages, and makes an impact on, the most relevant social and environmental issues for the company and its stakeholders.  

  • Innovation – contributing to more sustainable health care systems by improving outcomes, reducing costs and protecting patients and health care workers
  • Access – supporting health system improvements in emerging and developing economies, and reaching vulnerable populations globally
  • Efficiency – working across the value chain to reduce environmental impacts and create positive social impact
  • Empowerment – advancing a purpose-driven culture through workforce and community engagements

Highlights from this year’s report include:

  • Innovation: In FY 2019, BD launched 25 products across the company’s three businesses – Medical, Interventional and Life Sciences – further increasing access to quality health care. The company continues to identify opportunities for innovation to help address health care challenges and drive business performance.
  • Access: In August 2019, BD was recognized for its third time in five years by Fortune magazine, and named to its «Change the World List» for the company’s extensive efforts in helping combat the threat of antimicrobial resistance (AMR) through programs that raise awareness of AMR, as well as mobilize the health care industry, leaders and communities around the world to take action to extend the useful life of medications.
  • Efficiency: Since setting its 2020 Sustainability targets in 2015, BD has continued to reduce its greenhouse gas emissions and water consumption, and remains committed to waste reduction, and increasing use of renewable energy, including the installation of on-site solar power generation across BD’s sites – most recently at the company’s global headquarters in Franklin Lakes, NJ. Over the course of FY 2019, the company identified more than 200 energy reduction projects that will amount to over $5 million in energy savings, once completed. Projects include the replacement of existing lighting with LED lighting, recommissioning of an ice plant, combined heat and power projects, installation of solar panel projects and various equipment upgrades.
  • Empowerment: BD is committed to fostering an environment that welcomes and empowers an inclusive and diverse workforce which has earned the company recognition by a number of organizations in 2019, including the Human Rights Campaign Foundation (Best Place to Work for LGBTQ Equality), Bloomberg (2020 Gender Equality Index), and Forbes (Best Employers for Diversity 2020), among others. The company continues to place a strong focus on philanthropy, providing $10 million in cash donations and $14 million in product donations, as well as expertise and employee volunteer hours to non-profit organizations around the world.

«We are proud of our accomplishments in FY 2019, but we will never be satisfied with maintaining the status quo,» said Tom Polen, CEO and president. «Just as we continuously seek new innovations to help more patients live better lives, we strive to be the best employer, the best environmental steward and the best global corporate citizen we can possibly be.»

The company will announce new sustainability commitments later in FY 2021 which will focus on shared value creation – addressing unmet societal needs through business models and initiatives that also contribute to commercial success. For more information about the company’s sustainability goals, view the 2019 Sustainability Report here: https://www.bd.com/en-us/company/sustainability-at-bd.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com

Contacts:

Jessica Offerjost 

Monique N. Dolecki

BD Public Relations 

BD Investor Relations

201-258-0964 

201.847.5378

Jessica.Offerjost@bd.com

Monique_Dolecki@bd.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bd-releases-fy-2019-sustainability-report-301104250.html

SOURCE BD (Becton, Dickinson and Company)

BD releases FY 2019 Sustainability Report

FRANKLIN LAKES, N.J., Aug. 3, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2019 Sustainability Report, focusing on performance of the environmental, social and governance factors that support the company’s

FRANKLIN LAKES, N.J., Aug. 3, 2020 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today issued its 2019 Sustainability Report, focusing on performance of the environmental, social and governance factors that support the company’s 2020 Sustainability Goals from October 1, 2018 to September 30, 2019 (FY 2019).

BD’s sustainability strategy is driven by its purpose – Advancing the world of health™ – and provides the framework for how it manages, and makes an impact on, the most relevant social and environmental issues for the company and its stakeholders.  

  • Innovation – contributing to more sustainable health care systems by improving outcomes, reducing costs and protecting patients and health care workers
  • Access – supporting health system improvements in emerging and developing economies, and reaching vulnerable populations globally
  • Efficiency – working across the value chain to reduce environmental impacts and create positive social impact
  • Empowerment – advancing a purpose-driven culture through workforce and community engagements

Highlights from this year’s report include:

  • Innovation: In FY 2019, BD launched 25 products across the company’s three businesses – Medical, Interventional and Life Sciences – further increasing access to quality health care. The company continues to identify opportunities for innovation to help address health care challenges and drive business performance.
  • Access: In August 2019, BD was recognized for its third time in five years by Fortune magazine, and named to its «Change the World List» for the company’s extensive efforts in helping combat the threat of antimicrobial resistance (AMR) through programs that raise awareness of AMR, as well as mobilize the health care industry, leaders and communities around the world to take action to extend the useful life of medications.
  • Efficiency: Since setting its 2020 Sustainability targets in 2015, BD has continued to reduce its greenhouse gas emissions and water consumption, and remains committed to waste reduction, and increasing use of renewable energy, including the installation of on-site solar power generation across BD’s sites – most recently at the company’s global headquarters in Franklin Lakes, NJ. Over the course of FY 2019, the company identified more than 200 energy reduction projects that will amount to over $5 million in energy savings, once completed. Projects include the replacement of existing lighting with LED lighting, recommissioning of an ice plant, combined heat and power projects, installation of solar panel projects and various equipment upgrades.
  • Empowerment: BD is committed to fostering an environment that welcomes and empowers an inclusive and diverse workforce which has earned the company recognition by a number of organizations in 2019, including the Human Rights Campaign Foundation (Best Place to Work for LGBTQ Equality), Bloomberg (2020 Gender Equality Index), and Forbes (Best Employers for Diversity 2020), among others. The company continues to place a strong focus on philanthropy, providing $10 million in cash donations and $14 million in product donations, as well as expertise and employee volunteer hours to non-profit organizations around the world.

«We are proud of our accomplishments in FY 2019, but we will never be satisfied with maintaining the status quo,» said Tom Polen, CEO and president. «Just as we continuously seek new innovations to help more patients live better lives, we strive to be the best employer, the best environmental steward and the best global corporate citizen we can possibly be.»

The company will announce new sustainability commitments later in FY 2021 which will focus on shared value creation – addressing unmet societal needs through business models and initiatives that also contribute to commercial success. For more information about the company’s sustainability goals, view the 2019 Sustainability Report here: https://www.bd.com/en-us/company/sustainability-at-bd.

About BD

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com

Contacts:

Jessica Offerjost 

Monique N. Dolecki

BD Public Relations 

BD Investor Relations

201-258-0964 

201.847.5378

Jessica.Offerjost@bd.com

Monique_Dolecki@bd.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/bd-releases-fy-2019-sustainability-report-301104250.html

SOURCE BD (Becton, Dickinson and Company)

Lannett Announces Launch Of FDA Approved Levothyroxine Tablets

PHILADELPHIA, Aug. 3, 2020 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today announced the launch of Cediprof, Inc.’s FDA approved Levothyroxine Sodium Tablets USP, under the companies recently announced interim exclusive supply and distribution agreement.

PHILADELPHIA, Aug. 3, 2020 /PRNewswire/ — Lannett Company, Inc. (NYSE: LCI) today announced the launch of Cediprof, Inc.’s FDA approved Levothyroxine Sodium Tablets USP, under the companies recently announced interim exclusive supply and distribution agreement.

The companies also said they have prevailed in separate legal challenges by Cediprof’s previous distributor of the product. Judges in two courts denied a request by the previous distribution partner for a temporary restraining order that sought to enjoin Cediprof from terminating the prior agreement and transferring distribution rights to Lannett.

Lannett said the rulings removed a potential hurdle for it to commence distributing the product in the U.S., notwithstanding any ongoing dispute with Cediprof’s prior partner on the earlier termination.

Cediprof, Inc. is a part of the Neolpharma Pharmaceutical Group family of companies.

About Neolpharma Pharmaceutical Group:
Neolpharma Pharmaceutical Group engages in the research, development, production and distribution of generic medicines in the following therapeutic areas: CNS, oncology, metabolic disease, rheumatology and infectious diseases. Based in Mexico City, Mexico, Neolpharma Group has affiliates and operations in Puerto Rico, the U.S. and Latin America. For more information, visit the company’s website at www.neolpharma.com.

About Lannett Company, Inc.:
Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications. For more information, visit the company’s website at www.lannett.com .

This news release contains certain statements of a forward-looking nature relating to future events or future business performance. Any such statement, including, but not limited to, the company successfully commercializing Levothyroxine Sodium Tablets, and the potential material impact of COVID-19 on future financial results, whether expressed or implied, is subject to market and other conditions, and subject to risks and uncertainties which can cause actual results to differ materially from those currently anticipated due to a number of factors which include, but are not limited to, the risk factors discussed in the Company’s Form 10-K and other documents filed with the SEC from time to time, including the prospectus supplement related to the proposed offering to be filed with the SEC. These forward-looking statements represent the Company’s judgment as of the date of this news release. The Company disclaims any intent or obligation to update these forward-looking statements.

Contact:

Robert Jaffe

Robert Jaffe Co., LLC

(424) 288-4098

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/lannett-announces-launch-of-fda-approved-levothyroxine-tablets-301104249.html

SOURCE Lannett Company, Inc.